NCT00831415 - Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD) | Biotech Hunter

Enrollment

304

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Major Depressive Disorder

Interventions

DRUG

desvenlafaxine succinate sustained release tablets

25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.

Trial Locations (17)

Pfizer Investigational Site, Aichi

Pfizer Investigational Site, Chiba

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Fukushima

Pfizer Investigational Site, Gunma

Pfizer Investigational Site, Hiroshima

Pfizer Investigational Site, Hokkaido

Pfizer Investigational Site, Hyōgo

Pfizer Investigational Site, Ishikawa

Pfizer Investigational Site, Kanagawa

Pfizer Investigational Site, Kumamoto

Pfizer Investigational Site, Kyoto

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Saga

Pfizer Investigational Site, Saitama

Pfizer Investigational Site, Shiga

Pfizer Investigational Site, Tokyo